Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune system monitoring in children with neuroblastoma
NL-OMON52494Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dinutuximab in neuroblastoma, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Immune profiles during therapy, Immune cell percentages and absolute numbers and 4 more. Started Mar 2023; status: recruiting.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON52494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52494.